H.C. Wainwright raised its price target for Calithera Biosciences (NASDAQ:CALA) to $14 from $10, citing a recent partnership with Incyte and dilution from recent rounds of fund raising. The stock closed at $10.75 on March 28.Read More
BioTime (NYSE MKT:BTX) is expanding its ongoing Phase 1/2a clinical trial for OpRegen in the advanced dry form of AMD by naming the first two sites that will treat patients in the U.S.Read More
Histogenics (NASDAQ:HSGX) announced the online peer-reviewed publication in the Journal of Orthopaedic Research that analyzes mechanical properties of tissue engineered cartilage based on work done as part of a sponsored-research agreement between Histogenics and Dr. Lawrence Bonassar at Cornell University.Read More
BTIG initiated coverage of Organovo Holdings (NASDAQ:ONVO) with a “buy” rating and $5 price target. The stock closed at $3.69 on Dec. 14.Read More
ContraVir Pharmaceuticals (NASDAQ:CTRV) provided new insights into the mechanism of action of its hepatitis B (HBV) cyclophilin inhibitor, CRV431, showing that it effectively blocks a critical interaction between HBV X protein (HBx) and host cyclophilin A, with nanomolar potency.Read More
Results of Mesoblast’s (NASDAQ:MESO; ASX:MSB) Phase 2 trial of its allogeneic mesenchymal precursor cell (MPC) product candidate, MPC-300-IV, in patients with diabetic kidney disease have been published in the current issue of the peer-reviewed journal, EBioMedicine.
The paper concluded that a single intravenous infusion of MPC-300-IV was well tolerated and had positive effects on renal function at the 12-week primary endpoint in the trial with adult patients with Type 2 diabetic nephropathy.Read More
BioLight Life Sciences (TASE:BOLT) reported promising results from a feasibility clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect technology.
The study successfully demonstrated the feasibility of detecting intact cells originating in the prostate from urine samples following prostate massage.Read More
Rodman & Renshaw has initiated coverage of BioBlast Pharma (NASDAQ:ORPN) with a “buy” rating and 12-month price target of $25. The stock closed at $3.24 on Wednesday.
BioBlast is focused on platform-based solutions, addressing rare diseases due to mitochondrial dysfunction and misfolding of critical function proteins.Read More